How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/non-infectious-intermediate-posterior-and-panuveitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Non-infectious intermediate, posterior and panuveitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-infectious intermediate, posterior and panuveitis (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Non-infectious intermediate, posterior and panuveitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Abrilada	Adalimumab-Afzb	AbbVie	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
CYLTEZO	ADALIMUMAB-ADBM	BOEHRINGER INGELHEIM		Tumor necrosis factor
Humira	Humira	Sohag University		Tumor necrosis factor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AbbVie · 2 drugs in Non-infectious intermediate, posterior and panuveitis
BOEHRINGER INGELHEIM · 1 drug in Non-infectious intermediate, posterior and panuveitis
Sohag University · 1 drug in Non-infectious intermediate, posterior and panuveitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Non-infectious intermediate, posterior and panuveitis:

Cite this brief

Drug Landscape (2026). Non-infectious intermediate, posterior and panuveitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/non-infectious-intermediate-posterior-and-panuveitis. Accessed 2026-06-10.

Non-infectious intermediate, posterior and panuveitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing